NewsBenzingaUCBとBiogen、PHOENYCS GO第3相試験の事後解析で、Dapirolizumab Pegol+標準治療はプラセボと比較して新規TRM-SLEにおける高い奏効率およびより持続的な低疾患活動性を示したと報告 UCBとBiogen、PHOENYCS GO第3相試験の事後解析で、Dapirolizumab Pegol+標準治療はプラセボと比較して新規TRM-SLEにおける高い奏効率およびより持続的な低疾患活動性を示したと報告 Benzinga 2026.11.09 06:56 (GMT+0) Open on Benzinga Other news Nvidia Forms Board Panel for Export-Control Oversight Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free NVIDIA Board Establishes National Security and Export Control Oversight Committee Is Wall Street Bullish or Bearish on Ferguson Enterprises Stock? Nvidia Board Not Considering Jensen Huang's Return: Report Lighter Releases Security Incident Statement: API Key Leak Led to User Fund Theft, About $5 Million in USDC Recovered
Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free
Lighter Releases Security Incident Statement: API Key Leak Led to User Fund Theft, About $5 Million in USDC Recovered